Binding affinity to HSPA2 in human Jurkat cells at 150 uM followed by UV irradiation for 30 mins with Wood's glass filtered medium pressure mercury arc light after cell lysis measured after denaturing wash by SDS-PAGE based pull down assay
Binding affinity to HSPA2 in human Jurkat cells at 150 uM followed by UV irradiation for 30 mins with Wood's glass filtered medium pressure mercury arc light prior to cell lysis measured after denaturing wash by SDS-PAGE based pull down assay
Binding affinity to HSPA2 in human Jurkat cells at 150 uM followed by UV irradiation for 30 mins with Wood's glass filtered medium pressure mercury arc light prior to cell lysis measured after denaturing wash by LC-MS/MS based pull down assay
Inhibition of (2S,8S,11S,14S)-2-(4-aminobutyl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-11-(hydroxymethyl)-4,7,10,13,16,32-hexaoxo-36-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-19,22,25,28-tetraoxa-3,6,9,12,15,31-hexaazahexatriacontan-1-oic acid binding to human Hsp72 SBD expressed in Escherichia coli BL21 (DE3) up to 200 uM by Western blot analysis based pull down assay
Inhibition of (2S,8S,11S,14S)-2-(4-aminobutyl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-11-(hydroxymethyl)-4,7,10,13,16,32-hexaoxo-36-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-19,22,25,28-tetraoxa-3,6,9,12,15,31-hexaazahexatriacontan-1-oic acid binding to human Hsp72 SBD expressed in Escherichia coli BL21 (DE3) by Western blot analysis
Inhibition of (2S,8S,11S,14S)-2-(4-aminobutyl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-11-(hydroxymethyl)-4,7,10,13,16,32-hexaoxo-36-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-19,22,25,28-tetraoxa-3,6,9,12,15,31-hexaazahexatriacontan-1-oic acid binding to human Hsp72 SBD expressed in Escherichia coli BL21 (DE3) by Western blot analysis based pull down assay
Covalent inhibition of HSP72-NBD (unknown origin) assessed as Kinact/Ki ratio after 0.083 hrs nucleotide-derived FP probe displacement based by fluorescence polarization assay
Covalent inhibition of HSP72-NBD (unknown origin) assessed as Kinact/Ki ratio after 19 hrs nucleotide-derived FP probe displacement based by fluorescence polarization assay
Covalent inhibition of HSP72-NBD (unknown origin) assessed as Kinact/Ki ratio after 0.083 to 2 hrs nucleotide-derived FP probe displacement based by fluorescence polarization assay
Covalent inhibition of HSP72-NBD (unknown origin) assessed as Kinact/Ki ratio nucleotide-derived FP probe displacement based by fluorescence polarization assay